Replies to post #11439 on Momenta Pharmaceuticals, Inc. (MNTA)

[imnot6]

Because MNTA remains a high-beta speculative stock that regularly over-responds as much due to money flow into and out of the biotech sector in general as it does to data specific to its NPV?

[DewDiligence]

Synthon’s PR is positive for MNTA insofar as it makes no suggestion that Synthon is close to obtaining FDA approval or that the 505(j) pathway is the wrong way to proceed (#msg-99563993).